GUANGZHOU, China — December 23, 2025 — Leads & Copy — Burning Rock Biotech Limited (NASDAQ: BNR) announced that all shareholder resolutions proposed at the Company’s 2025 annual general meeting held Monday were duly passed.
Shareholders ratified the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 and authorized the directors of the Company to determine the remuneration of the auditor.
Shareholders also re-elected Feng Deng and Licen Lisa Xu as directors of the Company.
Each of the directors of the Company were authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
Burning Rock Biotech Limited (NASDAQ: BNR) focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
Contact: IR@brbiotech.com
Source: Burning Rock Biotech Limited
